GENERATION BIO CO (GBIO)
US37148K1007 - Common Stock
Overall GBIO gets a fundamental rating of 3 out of 10. We evaluated GBIO against 572 industry peers in the Biotechnology industry. GBIO has a great financial health rating, but its profitability evaluates not so good. GBIO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
GBIO had negative earnings in the past year.
GBIO had a negative operating cash flow in the past year.
In the past 5 years GBIO always reported negative net income.
GBIO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
GBIO has a Return On Assets (-58.47%) which is in line with its industry peers.
GBIO has a worse Return On Equity (-139.28%) than 62.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.47% | ||
| ROE | -139.28% | ||
| ROIC | N/A |
ROA(3y)-31.7%
ROA(5y)-53.62%
ROE(3y)-47.3%
ROE(5y)-106.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GBIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GBIO has been increased compared to 1 year ago.
Compared to 5 years ago, GBIO has more shares outstanding
GBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -4.04, we must say that GBIO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.04, GBIO is in line with its industry, outperforming 40.71% of the companies in the same industry.
There is no outstanding debt for GBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.04 |
ROIC/WACCN/A
WACC10.88%
2.3 Liquidity
A Current Ratio of 6.34 indicates that GBIO has no problem at all paying its short term obligations.
GBIO has a Current ratio of 6.34. This is in the better half of the industry: GBIO outperforms 63.89% of its industry peers.
A Quick Ratio of 6.34 indicates that GBIO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.34, GBIO is in the better half of the industry, outperforming 64.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.34 | ||
| Quick Ratio | 6.34 |
3. Growth
3.1 Past
GBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.61%.
The Revenue has grown by 513.27% in the past year. This is a very strong growth!
GBIO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 171.53% yearly.
EPS 1Y (TTM)-10.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.51%
Revenue 1Y (TTM)513.27%
Revenue growth 3YN/A
Revenue growth 5Y171.53%
Sales Q2Q%252%
3.2 Future
GBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.99% yearly.
The Revenue is expected to grow by 23.96% on average over the next years. This is a very strong growth
EPS Next Y4.24%
EPS Next 2Y19.6%
EPS Next 3Y15.3%
EPS Next 5Y9.99%
Revenue Next Year370.54%
Revenue Next 2Y35.82%
Revenue Next 3Y34.54%
Revenue Next 5Y23.96%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GBIO. In the last year negative earnings were reported.
Also next year GBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as GBIO's earnings are expected to grow with 15.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.6%
EPS Next 3Y15.3%
5. Dividend
5.1 Amount
No dividends for GBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GENERATION BIO CO
NASDAQ:GBIO (1/14/2025, 8:00:01 PM)
Premarket: 0.9996 +0.12 (+13.59%)0.88
-0.04 (-4.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners84.39%
Inst Owner Change-0.01%
Ins Owners2.44%
Ins Owner Change0.12%
Market Cap58.78M
Analysts80
Price Target7.14 (711.36%)
Short Float %3.09%
Short Ratio4.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.52%
Min EPS beat(2)-9.16%
Max EPS beat(2)20.2%
EPS beat(4)1
Avg EPS beat(4)-43.46%
Min EPS beat(4)-169.03%
Max EPS beat(4)20.2%
EPS beat(8)4
Avg EPS beat(8)-19.39%
EPS beat(12)6
Avg EPS beat(12)-11.93%
EPS beat(16)8
Avg EPS beat(16)-6.88%
Revenue beat(2)2
Avg Revenue beat(2)199.05%
Min Revenue beat(2)104.65%
Max Revenue beat(2)293.44%
Revenue beat(4)4
Avg Revenue beat(4)183.37%
Min Revenue beat(4)104.65%
Max Revenue beat(4)293.44%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-18.07%
EPS NY rev (1m)0%
EPS NY rev (3m)9.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.92%
Revenue NY rev (1m)4.72%
Revenue NY rev (3m)56.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.16 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.56 | ||
| P/tB | 0.56 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.19
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-1.56
FCFYN/A
OCF(TTM)-1.46
OCFYN/A
SpS0.28
BVpS1.56
TBVpS1.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.47% | ||
| ROE | -139.28% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-31.7%
ROA(5y)-53.62%
ROE(3y)-47.3%
ROE(5y)-106.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 129.97% | ||
| Cap/Sales | 35.52% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.34 | ||
| Quick Ratio | 6.34 | ||
| Altman-Z | -4.04 |
F-Score4
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)147.89%
Cap/Depr(5y)335.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.51%
EPS Next Y4.24%
EPS Next 2Y19.6%
EPS Next 3Y15.3%
EPS Next 5Y9.99%
Revenue 1Y (TTM)513.27%
Revenue growth 3YN/A
Revenue growth 5Y171.53%
Sales Q2Q%252%
Revenue Next Year370.54%
Revenue Next 2Y35.82%
Revenue Next 3Y34.54%
Revenue Next 5Y23.96%
EBIT growth 1Y27.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.47%
EBIT Next 3Y10.49%
EBIT Next 5YN/A
FCF growth 1Y6.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.49%
OCF growth 3YN/A
OCF growth 5YN/A